Ipca Laboratories Ltd Q2 FY2023 Concall Summary

Source transcript PDF: https://assets.stockscans.in/docs/94jtypdhde7m6m967kxeo7t5.pdf

Key Takeaways


Domestic Formulations: The Growth Engine

Management: "Whenever you recruit the new people, it take time to-- for them to become productive. It will take almost around 2 years' time for them to start giving breakeven to the company. ... 3rd year onwards they will start contributing profits to the company."

API & Export Generics: The Problem Children

Management: "The major geographies where the impact has come is, one is Latin America, and one is Asia. These are the two geographies where the major impact we have seen is, basically because of slowdown in the demand and customers postponing the order executions."

Margins: Compressed Today, Building Blocks Tomorrow

Management: "Actually speaking, this financial year is very difficult, cost pressure, demand issues, so many regulatory problems with the API, Nitrosamines impurity and, plus, over and above that we have added about 1500 people in the domestic market. In spite of that we are delivering this kind of EBITDA margin."

UK & Institutional: Transition Stories

Management: "We are not projecting a significant growth as far as this category of business is concerned. And on institutional business we are there are only antimalarials. So, that's the kind of scenario over a longer period of time."

Facilities & Regulatory: Waiting on Catalysts

Management: "So, we see that overall, for 1 year nothing meaningful contributions would come from this site, till the time we file all the products and till the time regulatory inspections of the site happens."

Guidance & Commitments

CommitmentSpecificsTimeline
API full-year growthDecline of ~2% (2-3% degrowth)FY23
Export generics full-year growth2-3% degrowth (revised from ~5% growth)FY23
EBITDA marginRemain around 21%FY23
Marketing cost normalizationNormal cost increase of 8-10%From FY24
CIS/Russia branded export growth~15% growthFY23
UK full-year performanceMarginal declineFY23
Dewas meaningful contributionNo meaningful contribution for 1 year~Q3 FY24
New MR breakeven~2 years to breakeven; profit contribution from year 3FY25 onwards
Ramdev recoveryBack on track2-3 quarters
Pisgah recoveryRecoveryAnother year or so
Silvassa UK MHRA accreditationExpected~1 month

Key Metrics

MetricQ2 FY23
Revenue (domestic formulation)10% growth, antimalarial business declined ~19%
Revenue (domestic formulation ex-antimalarials)~13% growth
Revenue (export promotional business)~33% growth
Revenue (export generic business, including institutional)~8% growth
Revenue (institutional business)~12% growth
Revenue (generics business)~4% growth
Revenue (API business)~15% decline, full FY23 expected decline of 2-3%
Material cost to income32.83%, improved 0.26 ppt YoY from 33.09%
Other expenditure~23% increase YoY, energy cost higher by ~₹16 cr
EBITDA margin (standalone)21.04%, vs 23.05% in Q2 FY22
EBITDA margin guidance (full year)~21%
India business gross margin67-68%, consistent, not materially changed
MR addition cost impact (full FY23)₹120 cr to ₹150 cr overall, ~₹100 cr from new people added during the year
Market share (IPM)~1.91%, up from 1.86% over last 4 years
IPM rank17th, gained 3 ranks over 2018
Pain segment growth (domestic)~21% vs market growth of ~12%
Cardiac segment growth (domestic)~4% vs market growth of ~7%
CNS segment growth (domestic)~30% vs market growth of ~9%
Urology segment growth (domestic)~35% vs market growth of ~17%
Dermatology segment growth (domestic)~14% vs market growth of ~3%
Anti-infectives segment growth (domestic)~5% vs market growth of ~4%
Cough and cold segment growth (domestic)~24% vs market growth of ~12%
Branded export (CIS/Russia) growth~93% in Q2, full-year projection ~15%
USD realization (Q2)₹79.85/Dollar, average for H1 less than ₹80/Dollar
Silvassa facility utilization15-20% capacity
SEZ Indore facility utilization~35-40% capacity
Tax rate (effective, including deferred tax)~28-29%
Dewas facility cost addition (H2 FY23)~₹2.5 cr per month plus additional depreciation
Generic business guidance (full FY23, revised)2-3% degrowth, vs earlier ~5% growth guidance
EBITDA margin target (3-4 years out)24-25%